Lilly’s Retevmo®Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus the physician’s choice of the multikinase inhibitors (MKIs) cabozantinib…
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent…
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug…
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline…
MODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season…
Pfizer’s ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed…
Novartis Completes Acquisition of Chinook Therapeutics Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a…
Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE™ (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide…
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug…
AstraZeneca appoints Sharon Barr as Executive Vice President BioPharmaceuticals R&D AstraZeneca today announced the appointment of Sharon Barr as Executive Vice President, BioPharmaceuticals R&D. Sharon will succeed Mene Pangalos, who is retiring and will step down from his role early…
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.…
Enhertu demonstrated clinically meaningful progression-free survival and overall survival across multiple HER2-expressing advanced solid tumors in DESTINY-PanTumor02 Phase II trial High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS)…